approval
saveBLINCYTO (BLINATUMOMAB) — FDA approval
community read0 votes
Sponsor: AMGEN. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 2 completionAbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026 · 155d ago
- phase 2 completionSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)Apr 25, 2026 · 160d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalOct 21, 2025 · 346d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalDec 17, 2024 · 654d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 14, 2024 · 840d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalFeb 8, 2024 · 967d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1200d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1200d ago
same company · ±60 days · 6
- approvaleculizumab biosimilar: BKEMV (ECULIZUMAB-AEEB) — FDA approvalApr 18, 2025
- approvalAMJEVITA: AMJEVITA (ADALIMUMAB-ATTO) — FDA approvalMay 20, 2025
- approvalAMJEVITA: AMJEVITA (ADALIMUMAB-ATTO) — FDA approvalApr 7, 2025
- recallAmgen, Inc. recall (Cls II)Mar 26, 2025
- recallAmgen, Inc. recall (Cls II)Mar 26, 2025
- approvalENBREL (ETANERCEPT) — FDA approvalJun 18, 2025
comments(0)
5-min edit window · permanent after that